Home » Regions » Asia » Daiichi Sankyo reorganizes R&D in India

Daiichi Sankyo reorganizes R&D in India

Thursday, January 12, 2017

Daiichi Sankyo Company, Limited has announced its decision to close its research subsidiary, Daiichi Sankyo India Pharma Private Limited, to increase R&D productivity.

Daiichi Sankyo is reviewing its global R&D system with the aim of decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.

DSIN presently employs approximately 170 people, mainly engaged in conducting drug discovery research targeting infectious diseases and inflammation. Following its closure, the DSIN R&D pipeline (including research themes selected by the Global Health Innovative Technology Fund [GHIT Fund]) will be transferred to Daiichi Sankyo’s R&D Division.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!